Profound Medical (TSE:PRN) has released an update.
Profound Medical reported a robust 64% revenue growth in Q3 2024, fueled by its innovative TULSA-PRO® technology for prostate treatment. The company is shifting towards a traditional medtech model, thanks to favorable reimbursement changes, while continuing to invest in R&D and expanding its executive team to support ongoing growth. Despite a net loss of $9.4 million, the company remains optimistic about future revenue growth and market expansion.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
